Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heterotopic Ossification Clear all
Completed Early Phase 1 Interventional

Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy

NCT01539447
View directory record Official record
Conditions
Heterotopic Ossification
Interventions
Naproxen, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 80 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

NCT03188666
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
REGN2477, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Jul 21, 2026, 5:32 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Naproxen for the Prevention of HO After Complex Elbow Trauma

NCT00586365
View directory record Official record
Conditions
Heterotopic Ossification
Interventions
Naproxen
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Jul 21, 2026, 5:32 PM EDT
Recruiting No phase listed Observational

IL1 Inhibition in FOP

NCT06724562
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Anti-IL1 Therapy
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 21, 2026, 5:32 PM EDT
Terminated Phase 2 Interventional Results available

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects

NCT02521792
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 21, 2026, 5:32 PM EDT
Completed No phase listed Observational

A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)

NCT02322255
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Not listed
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
Up to 65 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Jul 21, 2026, 5:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.

NCT07024407
View directory record Official record
Conditions
Heterotopic Ossification (HO)
Interventions
Andecaliximab
Drug
Lead sponsor
Ashibio Inc
Industry
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Jul 21, 2026, 5:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT05394116
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Garetosmab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 5:32 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06508021
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Andecaliximab, Placebo
Drug
Lead sponsor
Ashibio Inc
Industry
Eligibility
2 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects

NCT02190747
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene, Placebo
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
6 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Jul 21, 2026, 5:32 PM EDT
Recruiting No phase listed Observational

The Fibrodysplasia Ossificans Progressiva (FOP) Registry

NCT02745158
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Not listed
Lead sponsor
The International FOP Association
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2040
U.S. locations
1
States / cities
North Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 21, 2026, 5:32 PM EDT
Recruiting Phase 2 Interventional

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

NCT05090891
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
INCB000928, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 99 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 5:32 PM EDT
Completed No phase listed Observational

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06064656
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Non-Interventional
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Not applicable Interventional Results available

Heterotopic Ossification Prophylaxis

NCT04867278
View directory record Official record
Conditions
Acetabular Fracture, Heterotopic Ossification
Interventions
External Beam Radiation (XRT), Debridement
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)

NCT02279095
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene dose level 1, Palovarotene dose level 2, Palovarotene dose level 3, Palovarotene dose level 4
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jul 21, 2026, 5:32 PM EDT
Terminated Not applicable Interventional Results available

HO Prophylaxis Therapy for Distal Humerus Fractures

NCT03724422
View directory record Official record
Conditions
Heterotopic Ossification, Humeral Fractures, Radiation Therapy
Interventions
Radiation
Radiation
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Jul 21, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

NCT03312634
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
4 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Jul 21, 2026, 5:32 PM EDT
Not listed Not applicable Interventional

Celecoxib for Primary Prophylaxis of Combat-Related Heterotopic Ossification

NCT01631669
View directory record Official record
Conditions
Ossification, Heterotopic
Interventions
Celecoxib
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Jul 21, 2026, 5:32 PM EDT